{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:01:00Z","timestamp":1789016460831,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007052","name":"MSKCC","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jmoldx.2023.11.009","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T18:24:31Z","timestamp":1702578271000},"page":"168-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing\u2013Based Clonality Testing in B-Cell and Plasma Cell Neoplasms"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9167-3205","authenticated-orcid":false,"given":"Ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5448-4635","authenticated-orcid":false,"given":"Caleb","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2218-1490","authenticated-orcid":false,"given":"Wayne","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6502-6445","authenticated-orcid":false,"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1505-7889","authenticated-orcid":false,"given":"Jeffrey","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Maciag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4048-8376","authenticated-orcid":false,"given":"Kseniya","family":"Petrova-Drus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6623-9431","authenticated-orcid":false,"given":"Menglei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinJuan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Vanderbilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8090-5448","authenticated-orcid":false,"given":"Benjamin","family":"Durham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Benhamida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4245-752X","authenticated-orcid":false,"given":"Mark D.","family":"Ewalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Roshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khedoudja","family":"Nafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Arcila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2023.11.009_bib1","first-page":"5630","article-title":"The application of minimal residual disease in hemato-oncology: a review of its current utility in trials, regulatory decisions and clinical practice","volume":"130","author":"Jones","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib2","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/bloodadvances.2017009845","article-title":"Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation","volume":"1","author":"Br\u00fcggemann","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib3","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","article-title":"A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia","volume":"104","author":"Bassan","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3389\/fonc.2019.00689","article-title":"Minimal residual disease in chronic lymphocytic leukemia: a new goal?","volume":"9","author":"Del Giudice","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib6","doi-asserted-by":"crossref","first-page":"21194","DOI":"10.1073\/pnas.1118357109","article-title":"High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment","volume":"108","author":"Logan","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jmoldx.2018.10.008","article-title":"Establishment of immunoglobulin heavy (IGH) chain clonality testing by next-generation sequencing for routine characterization of B-cell and plasma cell neoplasms","volume":"21","author":"Arcila","year":"2019","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-018-0652-y","article-title":"Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL","volume":"11","author":"Cheng","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib9","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2017.58","article-title":"Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma","volume":"31","author":"Martinez-Lopez","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib10","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41375-019-0508-7","article-title":"Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS","volume":"33","author":"Scheijen","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib11","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.3390\/ijms20112832","article-title":"Minimal residual disease monitoring with next-generation sequencing methodologies in hematological malignancies","volume":"20","author":"S\u00e1nchez","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/jcm7090288","article-title":"New molecular technologies for minimal residual disease evaluation in B-cell lymphoid malignancies","volume":"7","author":"Dogliotti","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166126","article-title":"Vidjil: a web platform for analysis of high-throughput repertoire sequencing","volume":"11","author":"Duez","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib14","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41375-019-0499-4","article-title":"Quality control and quantification in IG\/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS","volume":"33","author":"Knecht","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fonc.2019.00449","article-title":"Standardized minimal residual disease detection by next-generation sequencing in multiple myeloma","volume":"9","author":"Yao","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.14420","article-title":"Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia","volume":"176","author":"Sekiya","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib18","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: WHO Classification of Tumours","year":"2017"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jmoldx.2020.10.015","article-title":"Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: feasibility, challenges, and direct comparison with high-sensitivity flow cytometry","volume":"23","author":"Ho","year":"2021","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.b.22120","article-title":"Highly sensitive single tube B-lymphoblastic leukemia\/lymphoma minimal\/measurable residual disease test robust to surface antigen directed therapy","volume":"104","author":"Gao","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib21","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1002\/cpz1.503","article-title":"Minimal\/measurable disease analysis in chronic lymphocytic leukemia\/small lymphocytic lymphoma by flow cytometry","volume":"2","author":"Gao","year":"2022","journal-title":"Curr Protoc"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib22","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib23","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib24","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/leu.2013.52","article-title":"Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia","volume":"27","author":"Logan","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib25","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib26","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib27","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib28","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-021-01135-w","article-title":"Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma","volume":"14","author":"Martinez-Lopez","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib30","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/bloodadvances.2021004234","article-title":"Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia","volume":"5","author":"Muffly","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib32","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib33","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib34","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib35","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood.2022017411","article-title":"Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL","volume":"141","author":"Hengeveld","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib36","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1111\/bjh.16571","article-title":"Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia","volume":"189","author":"Giusti","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib37","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.leu.2400986","article-title":"Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"12","author":"Schenk","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib38","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1101\/gad.1195504","article-title":"Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis","volume":"18","author":"Daser","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib39","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3324\/haematol.2020.249649","article-title":"Myeloid\/lymphoid neoplasms with eosinophilia\/basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition","volume":"106","author":"Yao","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib40","doi-asserted-by":"crossref","first-page":"951","DOI":"10.5858\/2007-131-951-QOPCIB","article-title":"Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment","volume":"131","author":"Smock","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jmoldx.2023.11.009_bib41","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157823002945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157823002945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:18:43Z","timestamp":1761502723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157823002945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1525157823002945"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2023.11.009","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing\u2013Based Clonality Testing in B-Cell and Plasma Cell Neoplasms","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2023.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}